These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 28657220)

  • 1. Prognostic models for locally advanced cervical cancer: external validation of the published models.
    Lora D; Gómez de la Cámara A; Fernández SP; Enríquez de Salamanca R; Gómez JFPR
    J Gynecol Oncol; 2017 Sep; 28(5):e58. PubMed ID: 28657220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-treatment MRI minimum apparent diffusion coefficient value is a potential prognostic imaging biomarker in cervical cancer patients treated with definitive chemoradiation.
    Marconi DG; Fregnani JH; Rossini RR; Netto AK; Lucchesi FR; Tsunoda AT; Kamrava M
    BMC Cancer; 2016 Jul; 16():556. PubMed ID: 27469349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postreatment squamous cell carcinoma antigen as a survival prognostic factor in patients with locally advanced cervical cancer. A Spanish multicenter study. The SEGO Spain-GOG group.
    Benito V; Lubrano A; Pérez-Regadera JF; Torné A; Gil-Moreno A; Tejerizo-Garcia Á; Vergés R; Díaz-Feijoo B;
    Gynecol Oncol; 2021 Aug; 162(2):407-412. PubMed ID: 34119366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
    Chen CC; Wang L; Lin JC; Jan JS
    J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy.
    Rose PG; Java J; Whitney CW; Stehman FB; Lanciano R; Thomas GM; DiSilvestro PA
    J Clin Oncol; 2015 Jul; 33(19):2136-42. PubMed ID: 25732170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic nomogram for overall survival in stage IIB-IVA cervical cancer patients treated with concurrent chemoradiotherapy.
    Tseng JY; Yen MS; Twu NF; Lai CR; Horng HC; Tseng CC; Chao KC; Juang CM
    Am J Obstet Gynecol; 2010 Feb; 202(2):174.e1-7. PubMed ID: 19931041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of R2* obtained from T2*-weighted imaging in predicting the prognosis of advanced cervical squamous carcinoma treated with concurrent chemoradiotherapy.
    Li XS; Fan HX; Fang H; Song YL; Zhou CW
    J Magn Reson Imaging; 2015 Sep; 42(3):681-8. PubMed ID: 25581675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
    Wang W; Hou X; Yan J; Shen J; Lian X; Sun S; Liu Z; Meng Q; Wang D; Zhao M; Qiu J; Hu K; Zhang F
    BMC Cancer; 2017 Aug; 17(1):510. PubMed ID: 28764676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk assessment model for overall survival in patients with locally advanced cervical cancer treated with definitive concurrent chemoradiotherapy.
    Shim SH; Lee SW; Park JY; Kim YS; Kim DY; Kim JH; Kim YM; Kim YT; Nam JH
    Gynecol Oncol; 2013 Jan; 128(1):54-59. PubMed ID: 23063760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
    Fujiwara M; Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Sumida I; Hayashi K; Kimura T; Ogawa K
    J Radiat Res; 2015 Mar; 56(2):305-14. PubMed ID: 25428244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modified Glasgow prognostic score is an independent prognostic factor in patients with cervical cancer undergoing chemoradiotherapy.
    Xiao Y; Ren YK; Cheng HJ; Wang L; Luo SX
    Int J Clin Exp Pathol; 2015; 8(5):5273-81. PubMed ID: 26191228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nomograms Combining Clinical and Imaging Parameters to Predict Recurrence and Disease-free Survival After Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer.
    Zhang Y; Liu L; Zhang K; Su R; Jia H; Qian L; Dong J
    Acad Radiol; 2023 Mar; 30(3):499-508. PubMed ID: 36050264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integration Pattern of Human Papillomavirus Is a Strong Prognostic Factor for Disease-Free Survival After Radiation Therapy in Cervical Cancer Patients.
    Joo J; Shin HJ; Park B; Park SY; Yoo CW; Yoon KA; Kong SY; Kim YJ; Kim SS; Kim JY
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(3):654-661. PubMed ID: 28581408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of Severe Lymphopenia During Pelvic Concurrent Chemoradiotherapy in Cervical Cancer.
    Cho O; Chun M; Chang SJ; Oh YT; Noh OK
    Anticancer Res; 2016 Jul; 36(7):3541-7. PubMed ID: 27354621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk assessment tool for distant recurrence after platinum-based concurrent chemoradiation in patients with locally advanced cervical cancer: a Korean gynecologic oncology group study.
    Kang S; Nam BH; Park JY; Seo SS; Ryu SY; Kim JW; Kim SC; Park SY; Nam JH
    J Clin Oncol; 2012 Jul; 30(19):2369-74. PubMed ID: 22614984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of chemoradiotherapy in cervical cancer--the Western Australian experience.
    Lim A; Sia S
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1431-8. PubMed ID: 21640504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computed Tomography-Planned High-Dose-Rate Brachytherapy for Treating Uterine Cervical Cancer.
    Zolciak-Siwinska A; Gruszczynska E; Bijok M; Jonska-Gmyrek J; Dabkowski M; Staniaszek J; Michalski W; Kowalczyk A; Milanowska K
    Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):87-92. PubMed ID: 27375169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of histological subtype on survival in patients with locally advanced cervical cancer that were treated with definitive radiotherapy: adenocarcinoma/adenosquamous carcinoma versus squamous cell carcinoma.
    Yokoi E; Mabuchi S; Takahashi R; Matsumoto Y; Kuroda H; Kozasa K; Kimura T
    J Gynecol Oncol; 2017 Mar; 28(2):e19. PubMed ID: 28028992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of total lesion glycolysis measured by 18F-FDG PET/CT in patients with locally advanced cervical cancer.
    Hong JH; Jung US; Min KJ; Lee JK; Kim S; Eo JS
    Nucl Med Commun; 2016 Aug; 37(8):843-8. PubMed ID: 27058362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. External validation of a combined PET and MRI radiomics model for prediction of recurrence in cervical cancer patients treated with chemoradiotherapy.
    Lucia F; Visvikis D; Vallières M; Desseroit MC; Miranda O; Robin P; Bonaffini PA; Alfieri J; Masson I; Mervoyer A; Reinhold C; Pradier O; Hatt M; Schick U
    Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):864-877. PubMed ID: 30535746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.